Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2014 | 09-2014 | 06-2014 | 03-2014 | 12-2013 | |
| Sales | 229,396 | 176,549 | 191,787 | 151,552 | 146,873 |
| Cost of Goods | 38,321 | 29,920 | 31,210 | 22,816 | 17,270 |
| Gross Profit | 191,075 | 146,629 | 160,577 | 128,736 | 129,603 |
| Operating Expenses | 250,152 | 136,346 | 179,669 | 156,008 | 182,183 |
| Operating Income | -58,756 | 11,203 | -18,882 | -26,456 | -52,310 |
| Interest Expense | 9,197 | 9,118 | 9,221 | 9,106 | 7,593 |
| Other Income | 2,216 | 1,136 | 375 | 938 | 528 |
| Pre-tax Income | -65,737 | 3,221 | -27,728 | -34,624 | -59,375 |
| Income Tax | 4,060 | -4,224 | 5,774 | 3,491 | 2,615 |
| Net Income Continuous | -69,797 | 7,445 | -33,502 | -38,115 | -61,990 |
| Net Income | $-69,797 | $7,445 | $-33,502 | $-38,115 | $-61,990 |
| EPS Basic Total Ops | -0.48 | 0.05 | -0.23 | -0.26 | -0.44 |
| EPS Basic Continuous Ops | -0.47 | 0.05 | -0.23 | -0.26 | -0.44 |
| EPS Diluted Total Ops | -0.47 | 0.05 | -0.23 | -0.27 | -0.43 |
| EPS Diluted Continuous Ops | -0.47 | 0.05 | -0.23 | -0.26 | -0.44 |
| EBITDA(a) | $-51,327 | $27,435 | $-3,365 | $-12,552 | $-52,074 |